Arrowhead Pharmaceuticals
Target the Gene, Silence the Disease
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a publicly traded (Nasdaq: ARWR) biopharmaceutical company that develops medicines using RNA interference (RNAi) to silence the genes that cause disease. Its therapies trigger the RNAi mechanism to knock down target genes and reduce the production of disease-causing proteins, and its pipeline includes candidates targeting diseases in the liver and lung. Its lead candidate is plozasiran (ARO-APOC3) for severe hypertriglyceridemia.
Industry
Biopharmaceuticals (RNAi therapeutics)
Headquarters
Pasadena, California, United States
Company size
711 employees (as of September 30, 2025)
What we do
RNA interference (RNAi) therapeuticsTRiM (Targeted RNAi Molecule) platformDrug development for genetic-based diseasesLiver-targeted disease programsLung-targeted disease programsCardiovascular/metabolic disease (e.g., severe hypertriglyceridemia)
Interested in Arrowhead Pharmaceuticals ?
Join our talent pool to be considered for future opportunities.